ARTICLE | Product Development
Trump’s statements sure to increase demand for COVID-19 mAbs
Lilly, Regeneron request EUAs for COVID-19 mAb therapies, Trump calls for immediate authorization
October 8, 2020 3:12 AM UTC
Just hours after Eli Lilly became the first COVID-19 mAb developer to disclose it had requested emergency use authorization, President Donald Trump released a video calling for immediate authorization of both Lilly’s and Regeneron’s mAbs, and asserted the therapies would be available free of charge.
The day ended with a statement from Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) that it has submitted a request for EUA of its mAb cocktail REGN-COV2 that was used in Trump’s treatment last week...
BCIQ Target Profiles